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Cancer	  is	  the	  leading	  cause	  of	  death	  in	  developed	  countries;	  it	  is	  also	  one	  of	  the	  most	  
costly	  diseases	  to	  treat.	  	  In	  the	  past	  decade,	  the	  cost	  of	  new	  cancer	  therapies	  has	  
risen	  exponentially.	  This,	  combined	  with	  the	  increasing	  cost	  of	  healthcare	  globally,	  
represents	  a	  significant	  economic	  burden	  for	  many	  if	  not	  all	  national	  governments.	  
This	  paper	  examines	  5	  different	  countries	  (Netherlands,	  Australia,	  the	  U.K.,	  Canada	  
and	  the	  U.S.)	  and	  their	  respective	  healthcare	  system.	  	  As	  well,	  this	  paper	  looks	  at	  
what	  policies	  are	  in	  place	  to	  ensure	  equitable	  care	  while	  evaluating	  whether	  these	  
new	  costly	  therapies	  are	  justifiably	  priced.	  Each	  country	  has	  a	  different	  mechanism	  
and/or	  threshold	  for	  evaluating	  cost-­‐effectiveness	  and	  therefore	  determining	  
whether	  a	  drug	  will	  be	  publicly	  funded.	  	  Finally,	  this	  paper	  suggests	  three	  different	  
solutions	  to	  make	  new	  cancer	  therapies	  more	  cost-­‐effective:	  government	  price	  
negotiations,	  tying	  drug	  approval	  to	  price	  negotiation,	  and	  pricing	  drugs	  based	  on	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Thesis:	  
	  
This	  paper	  examines	  how	  different	  countries	  deal	  with	  the	  high-­‐cost	  of	  new	  
oncology	  drug	  therapies.	  In	  particular,	  how	  countries	  with	  universal	  healthcare,	  
such	  as	  Canada,	  Australia,	  the	  U.S.,	  the	  U.K.,	  and	  the	  Netherlands	  have	  developed	  
strategic	  initiatives	  to	  deal	  with	  the	  financial	  burden	  of	  funding	  these	  new	  therapies.	  	  	  
1.1	  Introduction	  	  
	   	  
Cancer	  is	  the	  leading	  cause	  of	  death	  in	  Canada	  with	  an	  estimated	  187,600	  
new	  cases	  diagnosed	  in	  2013	  (Canadian	  Cancer	  Society's	  Advisory	  Committee	  on	  
Cancer	  Statistics	  May	  2013).	  It	  is	  responsible	  for	  almost	  30%	  of	  all	  mortalities	  
amounting	  to	  75,000	  deaths	  (Appendix	  1).	  	  While	  the	  disease	  has	  significant	  
personal	  and	  social	  impacts,	  it	  also	  has	  a	  major	  economic	  impact	  on	  a	  personal,	  
jurisdictional	  and	  national	  level	  (Canadian	  Cancer	  Society's	  Advisory	  Committee	  on	  
Cancer	  Statistics	  May	  2013).	  	  As	  one	  of	  the	  most	  costly	  diseases	  in	  Canada,	  spending	  
on	  cancer	  care	  amounted	  to	  $22.5	  billion	  in	  costs	  for	  2009,	  a	  change	  from	  $17.2	  
billion	  in	  2000	  (Canadian	  Cancer	  Society's	  Advisory	  Committee	  on	  Cancer	  Statistics	  
May	  2013,	  Thomson,	  Greve	  Young	  2011).	  	  Cancer	  is	  the	  second	  leading	  cause	  of	  
death	  in	  developed	  countries,	  not	  just	  Canada;	  its	  costs	  are	  unavoidable	  and	  the	  
economic	  burden	  is	  high.	  	  
The	  past	  decade	  has	  seen	  a	  huge	  shift	  in	  the	  way	  we	  treat	  disease.	  Now,	  new	  
therapies	  are	  not	  a	  one-­‐size-­‐fits-­‐all,	  but	  are	  referred	  to	  as	  targeted	  therapies.	  In	  May	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2001,	  and	  perhaps	  one	  of	  the	  most	  powerful	  and	  provoking	  examples,	  Time	  
Magazine	  featured	  a	  new	  drug	  called	  Gleevec	  on	  the	  cover.	  The	  headline	  read,	  
“There	  is	  new	  ammunition	  the	  war	  against	  cancer.	  These	  are	  the	  bullets”	  
(Buchdunger,	  Cioffi	  et	  al.	  2000,	  Heinrich,	  Griffith	  et	  al.	  2000,	  Pray	  2008).	  	  Gleevec,	  
used	  to	  treat	  a	  rare	  form	  of	  cancer	  called	  chronic	  myelogenous	  leukemia	  (CML),	  was	  
one	  of	  the	  first	  targeted	  therapies	  in	  the	  war	  against	  cancer.	  The	  drug	  targeted	  an	  
overactive	  receptor	  caused	  by	  a	  chromosomal	  translocation,	  referred	  to	  as	  the	  
Philadelphia	  chromosome.	  	  Gleevec	  changed	  the	  way	  doctors	  treated	  CML,	  resulting	  
in	  an	  increase	  of	  5-­‐year	  survival	  from	  30%	  to	  89%(Buchdunger,	  Cioffi	  et	  al.	  2000,	  
Heinrich,	  Griffith	  et	  al.	  2000,	  Pray	  2008).	  Gleevec	  was	  a	  miracle	  drug.	  	  
These	  miracle	  cures	  are	  costly,	  often	  accounting	  for	  27%	  of	  the	  total	  costs	  
(Uyl-­‐de	  Groot,	  de	  Groot	  et	  al.	  2010).	  And	  in	  light	  of	  the	  increasing	  cost	  of	  healthcare,	  
dealing	  with	  these	  swelling	  costs	  at	  both	  the	  individual	  and	  the	  societal	  level,	  while	  
retaining	  effective,	  equitable	  and	  accessible	  cancer	  care,	  poses	  a	  major	  challenge	  for	  
most	  health	  care	  systems	  (IMS	  Institute	  for	  Health	  Informatics	  2011).	  	  There	  is	  also	  
a	  widely	  held	  belief	  that	  higher	  spending	  always	  results	  in	  better	  outcomes	  for	  
patients	  with	  cancer	  (Porter	  2009,	  Uyl-­‐de	  Groot,	  deVries	  et	  al.	  2014,	  Philipson,	  Eber	  
et	  al.	  2012).	  Yet,	  this	  is	  not	  necessarily	  the	  case	  (Davis,	  Schoen	  et	  al.	  2010).	  There	  are	  
correlations	  that	  indicate	  the	  higher	  cost-­‐per-­‐capita	  expenditure	  on	  healthcare	  
result	  in	  outcomes	  such	  as	  increased	  life	  expectancy	  (Uyl-­‐de	  Groot,	  deVries	  et	  al.	  
2014).	  For	  example,	  a	  study	  by	  Phillipson	  et	  al	  showed	  that	  the	  average	  survival	  
from	  time	  of	  diagnosis	  was	  11.1	  years	  in	  the	  US,	  compared	  to	  9.3	  years	  in	  any	  
European	  country	  (Philipson,	  Eber	  et	  al.	  2012,	  Porter	  2009).	  This	  was	  attributed	  to	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the	  fact	  that	  the	  US	  spends	  the	  more	  per	  capita	  on	  healthcare	  than	  any	  European	  
country.	  However,	  there	  is	  conflicting	  evidence	  to	  suggest	  that	  is	  the	  case	  (Uyl-­‐de	  
Groot,	  deVries	  et	  al.	  2014).	  
1.1.1	  Factors	  Affecting	  Drug	  Cost	  
	  
	   Expensive	  new	  drugs	  are	  entering	  the	  market	  at	  a	  rapid	  pace.	  	  In	  2012,	  the	  
FDA	  approved	  12	  new	  cancer	  drugs	  (Experts	  in	  Chronic	  Myeloid	  Leukemia	  2013),	  
11	  of	  which	  cost	  €73,000	  per	  treatment	  per	  patient.	  But	  getting	  them	  funded	  with	  
their	  new	  outrageous	  price	  tags	  is	  another	  matter.	  At	  the	  time	  of	  its	  introduction	  in	  
Canada,	  Gleevec	  cost	  $24.35	  per	  pill,	  or	  approximately	  $30,000	  annually	  (Patented	  
Medicine	  Review	  Board	  2011).	  Yet	  now,	  over	  a	  decade	  later,	  the	  same	  treatment	  
costs	  an	  estimated	  $76,000	  (Cowley	  2013).	  
	   The	  price	  of	  new	  drugs	  has	  soared	  over	  the	  past	  several	  decades.	  The	  
demand	  for	  these	  life-­‐saving	  therapies	  is	  price-­‐inelastic.	  	  Why	  are	  they	  so	  expensive?	  	  
There	  are	  a	  lot	  of	  pre-­‐conceived	  notions	  regarding	  the	  cost	  of	  drugs	  several	  of	  which	  
may	  include	  greedy	  pharmaceutical	  companies	  and	  intellectual	  property	  issues.	  
However,	  the	  science	  of	  drug	  discovery	  is	  extremely	  difficult	  and	  the	  costs	  of	  
development	  are	  astronomical.	  This	  is	  the	  major	  reason	  drugs	  are	  so	  expensive	  
(Jogalekar	  2014).	  The	  complexity	  of	  biological	  systems	  is	  the	  reason	  that	  only	  32	  of	  
920	  drugs	  tested	  (1990-­‐2006)	  in	  the	  US	  made	  it	  through	  clinical	  trials	  (DiMasi,	  
Grabowski	  2007).	  The	  rate	  of	  failure	  is	  absurdly	  high.	  In	  fact,	  a	  higher	  percentage	  of	  
oncology	  drugs,	  compared	  to	  all	  other	  therapeutics	  classes,	  failed	  after	  entering	  
phase	  III	  testing	  (DiMasi,	  Grabowski	  2007).	  The	  average	  cost	  of	  development	  is	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anywhere	  from	  $1	  billion	  to	  $2	  billion	  dollars	  per	  drug	  (Pisano	  2006),	  although	  this	  
differs	  significantly	  depending	  on	  therapeutic	  class	  (Herper	  2010,	  DiMasi,	  
Grabowski	  2007).	  While	  many	  critics	  believe	  the	  actual	  cost	  of	  bringing	  a	  drug	  to	  
market	  is	  closer	  to	  $90	  million,	  which	  does	  not	  include	  and	  all	  the	  failed	  attempts	  
that	  resulting	  in	  one	  successful	  drug	  candidate	  (Besser	  2013).	  Innovation	  is	  
expensive.	  
	   The	  typical	  drug	  development	  process	  involves	  a	  finding	  target	  protein	  and	  
in	  vitro	  testing	  followed	  by	  extensive	  research	  in	  animal	  models	  (in	  vivo).	  	  Following	  
this,	  drugs	  must	  be	  approved	  to	  move	  forward	  into	  clinical	  testing.	  The	  clinical	  
testing	  phases	  range	  from	  phase	  I-­‐IV.	  Phase	  I	  involves	  testing	  the	  drug	  on	  a	  small	  
cohort	  to	  assess	  a	  drug’s	  safety	  profile,	  maximum	  tolerated	  dosage	  and	  side	  effects.	  	  
Phase	  II	  trials	  begin	  to	  look	  at	  whether	  a	  drug	  is	  effective	  and	  further	  evaluate	  its	  
safety	  in	  a	  larger	  group	  of	  patients.	  Phase	  III	  trials	  are	  the	  most	  crucial	  and	  involve	  
testing	  large	  groups	  of	  patients	  to	  evaluate	  the	  drug’s	  effectiveness,	  compare	  it	  to	  
the	  effectiveness	  of	  the	  current	  standard	  of	  care,	  and	  monitor	  the	  occurrence	  of	  side	  
effects	  in	  greater	  detail.	  	  The	  last	  phase,	  phase	  IV,	  is	  largely	  to	  monitor	  a	  drug’s	  
characteristics	  in	  different	  populations	  (demographics)	  and	  effects	  of	  long-­‐term	  use.	  
Additional	  costs	  imposed	  by	  regulatory	  bodies,	  such	  as	  the	  FDA,	  to	  increase	  the	  
timeliness	  of	  drug	  approval	  have	  also	  contributed	  to	  higher	  costs.	  
	   While	  drug	  development	  is	  a	  long	  and	  daunting	  process,	  there	  is	  some	  
evidence	  that	  these	  costs	  may	  be	  over	  exaggerated	  to	  justify	  the	  price	  tag.	  Estimates	  
have	  suggested	  the	  actual	  cost	  may	  be	  closer	  to	  4%	  to	  25%	  of	  the	  estimate	  (Light,	  
Warburton	  2011,	  Kantarjian,	  Fojo	  et	  al.	  2013).	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1.1.2	  Buyers	  as	  Price	  Makers:	  The	  Zaltrap	  Example	   	  
	  
Traditionally,	  large	  pharmaceutical	  companies	  have	  deeper	  pockets	  and	  
more	  bargaining	  power	  when	  it	  comes	  to	  selling	  and	  negotiating	  with	  governments.	  	  
Drug	  prices	  remain	  constant.	  That	  is,	  the	  supplier	  does	  not	  offer	  reduced	  prices	  in	  
order	  to	  maintain	  a	  consistent	  global	  price.	  Traditionally,	  the	  consumers	  are	  the	  
price	  takers.	  However,	  there	  is	  one	  exception	  to	  that	  rule	  when	  it	  comes	  to	  the	  drug	  
Zaltrap.	  	  
Zaltrap	  is	  a	  drug	  manufactured	  by	  Sanofi	  Oncology	  for	  metastatic	  colorectal	  
cancer.	  Zaltrap	  was	  introduced	  to	  the	  US	  market	  in	  2012	  at	  a	  price	  of	  $11,000	  per	  
month.	  However,	  after	  Zaltrap	  failed	  to	  be	  more	  effective	  than	  the	  cheaper	  gold	  
standard	  of	  care,	  Avastin,	  a	  major	  cancer	  center	  in	  the	  US,	  Sloan	  Kettering	  Memorial,	  
rejected	  it.	  In	  an	  unprecedented	  move,	  Sanofi	  decided	  to	  slash	  the	  price	  by	  50%	  
(Goldberg	  2012).	  Sanofi	  cited	  that	  ‘market	  resistance’	  was	  the	  real	  reason	  for	  the	  
reduction	  in	  price.	  	  
In	  general,	  pharmaceutical	  companies	  have	  different	  ways	  of	  making	  a	  drug	  
more	  cost-­‐effective.	  The	  reality	  is	  that	  drug	  pricing	  is	  full	  of	  confidential	  agreements,	  
typically	  referred	  to	  as	  risk-­‐sharing	  agreements	  (RSAs)	  or	  other	  price-­‐reduction	  
tactics	  collectively	  referred	  to	  as	  special-­‐pricing	  agreements	  (SPAS)	  (Cheema,	  
Gavura	  et	  al.	  2012).	  These	  could	  include	  price-­‐volume	  agreements,	  price	  or	  volume	  
caps,	  outcome	  based	  payments	  or	  rebates.	  Offering	  rebates	  is	  extremely	  common	  in	  
Canada.	  After	  a	  jurisdiction	  agrees	  to	  purchase	  and	  reimburse	  a	  drug,	  they	  can	  
submit	  a	  claim	  to	  the	  manufacturer	  and	  get	  a	  cash	  rebate	  (for	  example,	  for	  25%	  of	  
the	  drug	  cost)	  at	  year-­‐end.	  In	  a	  study	  of	  13	  different	  countries	  (including	  the	  ones	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discussed	  in	  this	  paper),	  9	  had	  taken	  part	  in	  some	  sort	  of	  RSAs	  for	  at	  least	  one	  
cancer	  drug	  (Cheema,	  Gavura	  et	  al.	  2012).	  Netherland	  was	  the	  one	  country	  
mentioned	  in	  this	  paper	  that	  had	  not	  taken	  part	  in	  one	  of	  these	  agreements	  
(Cheema,	  Gavura	  et	  al.	  2012).	  
	  
1.2	  The	  Basis	  for	  Drug	  Approval:	  Cost-­‐Effectiveness	  
Analysis	  (CEA)	  
	   	  
Most	  countries	  have	  a	  special	  committee	  that	  conducts	  a	  review	  process	  in	  
order	  to	  decide	  whether	  a	  drug	  should	  be	  publicly	  reimbursed.	  Canada	  has	  pCODR	  
for	  oncology	  drugs	  and	  the	  Common	  Drug	  Review	  (CDR)	  for	  all	  others.	  	  The	  CEA	  is	  
an	  economic	  analysis	  that	  relates	  health	  gains	  attributed	  to	  a	  drug	  to	  the	  net	  cost	  
associated	  with	  that	  particular	  drug’s	  use	  (or	  indication)	  (Cheema,	  Gavura	  et	  al.	  
2012,	  United	  Kingdom,	  Office	  of	  Fair	  Trading	  2007,	  Clement,	  Harris	  et	  al.	  2009).	  	  
	   The	  analysis	  is	  performed	  by	  pCODR.	  	  As	  mentioned,	  it	  not	  only	  takes	  into	  
account	  the	  price	  of	  purchasing	  a	  drug,	  but	  also	  its	  safety	  and	  effectiveness.	  The	  type	  
of	  CEA	  that	  is	  typically	  performed	  is	  called	  a	  cost-­‐utility	  analysis	  (CUA).	  The	  CUA	  
measures	  effectiveness	  in	  units	  called	  Quality-­‐Adjusted	  Life	  Years	  (QALYs).	  	  The	  
CUA	  evaluates	  the	  costs	  in	  relation	  to	  how	  a	  new	  drug	  performs	  to	  improve	  the	  
quality	  of	  life	  and	  the	  number	  of	  years	  lived	  when	  compared	  with	  other	  treatment	  
options,	  most	  commonly,	  the	  current	  gold	  standard	  of	  care.	  	  The	  QALY	  is	  the	  number	  
of	  additional	  years	  of	  life	  expected	  due	  to	  treatment	  multiplied	  by	  the	  quality	  of	  life	  
of	  the	  additional	  years.	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   The	  review	  committees	  in	  each	  country	  typically	  set	  an	  acceptable	  range	  for	  
cost	  per	  QALY.	  For	  example,	  in	  the	  UK,	  it	  is	  £20,000-­‐£30,000	  per	  QALY;	  in	  the	  U.S.	  it	  
is	  $50,000	  per	  QALY.	  In	  Canada	  there	  is	  no	  threshold	  value	  per	  se,	  but	  rather	  a	  range	  
of	  incremental	  cost	  per	  quality-­‐adjusted	  life-­‐year	  values	  ($20,000-­‐$100,000),	  and	  is	  
then	  considered	  in	  the	  context	  of	  a	  decision	  maker’s	  priorities	  (PCPA)	  and	  the	  
interventions’	  place	  in	  therapy.	  	  
1.2.1	  Incremental	  Cost	  Effectiveness	  Ratio	  (ICER)	  
	   	  
An	  incremental	  cost-­‐effectiveness	  ratio	  is	  also	  performed	  to	  compare	  the	  
efficacy	  of	  the	  new	  drug	  to	  an	  existing	  gold	  standard	  of	  care.	  It	  compares	  the	  cost	  
and	  health	  outcomes	  of	  two	  therapies	  that	  compete	  for	  the	  same	  resources.	  	  The	  
ICER	  ratio	  is	  the	  difference	  in	  cost	  of	  the	  two	  drugs	  divided	  by	  the	  difference	  in	  their	  
effectiveness,	  which	  will	  give	  you	  an	  incremental	  cost	  per	  QALY.	  Sometimes	  drugs	  
are	  ranked	  using	  the	  ICER	  ranking	  method	  to	  determine	  the	  most	  efficient	  way	  of	  
allocating	  funds	  in	  a	  static	  budget.	  	  This	  method	  ranks	  drugs	  from	  the	  least	  
additional	  cost	  for	  the	  most	  additional	  benefit	  (Pan-­‐Canadian	  Oncology	  Drug	  Review	  
and	  the	  Canadian	  Partnership	  Against	  Cancer	  2013).	  	  
1.2.2	  Criticisms	  of	  Pharmacoeconomic	  Analyses	  
	  
	   Cost-­‐effectiveness	  analysis	  is	  a	  widely	  accepted	  method	  for	  evaluating	  
innovative	  new	  therapies	  around	  the	  world.	  	  The	  UK	  uses	  CEA	  expressed	  as	  cost	  per	  
quality	  adjusted	  life	  year	  gained,	  while	  in	  the	  Netherlands,	  the	  Dutch	  Health	  
Insurance	  Board	  (CVZ)	  uses	  CEA	  criterion	  in	  their	  advice	  to	  the	  minister	  on	  adding	  
new	  technologies	  to	  their	  standard	  benefit	  package.	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But	  one	  of	  the	  major	  underlying	  assumptions	  for	  this	  analysis	  is	  that	  drug	  
cost	  and	  a	  drug’s	  effect	  remain	  constant	  over	  time	  (van	  de	  Wetering,	  Woertman	  et	  
al.	  2012).	  However,	  a	  study	  by	  Wetering	  et	  al.	  showed	  that	  is	  not	  the	  case,	  even	  in	  
the	  short	  run,	  and	  the	  costs	  may	  deviate	  significantly	  from	  the	  original	  CEA	  outcome	  
(van	  de	  Wetering,	  Woertman	  et	  al.	  2012).	  Additionally,	  a	  study	  by	  Yong	  et	  al	  
analyzed	  15	  different	  pharmacoeconomic	  drug	  submissions	  (Yong,	  Beca	  et	  al.	  2013).	  
They	  found	  that	  many	  of	  the	  analyses	  had	  significant	  problems	  that	  distorted	  the	  
results	  and	  were	  unable	  to	  determine	  the	  cost-­‐effectiveness	  of	  a	  drug	  suggesting	  
that	  there	  may	  be	  better	  and	  more	  critical	  ways	  to	  evaluate	  new	  therapeutics	  (Yong,	  
Beca	  et	  al.	  2013).
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2.0	  Different	  Jurisdictional	  Approaches	  
2.1	  Canada:	  A	  Historical	  Perspective	  on	  Drug	  Funding	  	  
	  
Following	  a	  drug’s	  approval	  by	  Health	  Canada,	  it	  is	  issued	  a	  notice	  of	  
compliance	  (NOC).	  This	  means	  the	  drug	  can	  legally	  be	  marketed	  and	  sold	  anywhere	  
in	  the	  country.	  However,	  for	  patients	  to	  gain	  access	  to	  a	  drug,	  it	  must	  be	  listed	  on	  a	  
provincial	  formulary,	  and	  each	  province	  has	  its	  own.	  	  
	   As	  a	  result	  of	  the	  individual	  provincial	  formularies,	  the	  long-­‐standing	  issue	  of	  
unequal	  access	  to	  cancer	  care	  across	  Canada	  has	  been	  deemed	  as	  a	  ‘postal	  code	  
lottery’	  or	  geographic	  lottery.	  	  	  For	  smaller	  provinces,	  this	  is	  particularly	  true,	  as	  
each	  province	  has	  it’s	  own	  healthcare	  budget,	  with	  larger	  provinces	  often	  having	  
more	  room	  in	  their	  budgets	  for	  expensive	  drug	  treatments.	  	  Larger	  provinces	  were	  
also	  approached	  first	  by	  drug	  manufacturers,	  so	  they	  often	  received	  access	  to	  new	  
drugs	  first.	  The	  way	  new	  drugs	  are	  funded	  in	  Canada	  has	  changed	  significantly	  in	  
the	  past	  3-­‐4	  years	  as	  result	  of	  the	  Pan-­‐Canadian	  Pricing	  Alliance.	  	  
2.1.1	  The	  Pan-­‐Canadian	  Pricing	  Alliance	  
	  
	   The	  pan-­‐Canadian	  pricing	  alliance	  (PCPA)	  was	  established	  in	  2010	  in	  an	  
effort	  to	  combat	  the	  high	  cost	  of	  new	  drugs	  in	  Canada.	  	  It	  was	  founded	  under	  the	  
Council	  of	  the	  Federation’s	  Healthcare	  Working	  Innovation	  Group.	  	  The	  PCPA	  
banded	  the	  buying	  power	  of	  multiple	  provinces	  combined	  and	  sought	  to	  make	  
pricing	  more	  consistent,	  increase	  the	  access	  to	  drug	  treatments	  options,	  and	  
improve	  the	  consistency	  of	  coverage	  criteria	  access	  across	  Canada.	  All	  of	  the	  
	   10	  
provinces,	  with	  the	  exception	  of	  Quebec	  and	  Nunavut,	  are	  participating	  in	  the	  PCPA.	  	  
Appendix	  1	  illustrates	  how	  the	  PCPA	  fits	  into	  the	  drug	  approval	  process	  in	  Canada.	  	  
After	  the	  CDR	  or	  PCODR	  releases	  its	  final	  recommendation	  on	  a	  drug,	  the	  
PCPA	  then	  discusses	  whether	  to	  proceed	  forward	  with	  negotiations	  for	  a	  particular	  
drug.	  One	  province	  steps	  up	  to	  take	  the	  lead	  in	  negotiating	  with	  the	  drug	  
manufacturer.	  If	  an	  acceptable	  agreement	  can	  be	  reached	  between	  participating	  
provinces	  and	  the	  manufacturer,	  a	  Letter	  of	  Intent	  will	  be	  signed	  by	  both	  negotiating	  
parties.	  The	  Letter	  of	  Intent	  will	  then	  be	  shared	  with	  all	  participating	  provinces.	  It	  is	  
then	  up	  to	  each	  province	  to	  make	  the	  final	  decision	  on	  funding	  the	  drug	  through	  the	  
PCPA	  agreement,	  or	  to	  enter	  into	  an	  agreement	  alone	  with	  the	  manufacturer.	  	  	  
Pricing	  negotiations	  with	  drug	  manufacturers	  only	  take	  into	  account	  
therapies	  that	  are	  new	  to	  the	  market	  and	  have	  yet	  to	  be	  funded,	  while	  the	  costs	  of	  
previously	  purchased/negotiated	  drugs	  remains	  high.	  Yet,	  there	  is	  a	  silver	  lining.	  	  
Occasionally,	  pre-­‐existing	  drugs	  gets	  marketed	  and	  approval	  for	  a	  new	  indication	  
and	  need	  to	  go	  through	  the	  process	  of	  getting	  that	  drug	  funded	  for	  the	  new	  
indication	  in	  each	  provincial	  formulary.	  The	  PCPA	  has	  the	  opportunity	  to	  
renegotiate	  the	  price	  of	  the	  drug	  with	  the	  manufacturer	  if	  they	  choose	  to	  fund	  the	  
drug	  for	  the	  new	  indication.	  	  
2.1.2	  Drug	  Pricing	  Prior	  to	  the	  PCPA	  
	  
Prior	  to	  the	  PCPA’s	  existence,	  the	  process	  was	  very	  similar,	  however,	  each	  
province	  did	  the	  negotiations	  with	  the	  manufacturer	  individually.	  Each	  province	  had	  
their	  own	  criteria	  for	  listing	  a	  drug	  and	  as	  a	  result,	  there	  was	  (and	  still	  is)	  variability	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in	  a	  drug’s	  listing	  status,	  a	  drug’s	  cost,	  coverage	  criteria	  and	  product	  listing	  
agreement.	  	  Larger	  provinces	  tended	  to	  receive	  better	  pricing	  agreements	  as	  a	  result	  
of	  the	  volume	  of	  expected	  sales.	  
	  
2.1.3	  The	  Rise	  of	  Privatized	  Care	  in	  Canada	  
	  
	   As	  a	  consequence	  of	  the	  irregular	  access	  to	  cancer	  drugs	  in	  Canada,	  the	  past	  
decade	  has	  seen	  a	  significant	  rise	  in	  the	  number	  of	  for-­‐profit	  medical	  clinics.	  	  These	  
specialty	  clinics	  have	  arisen	  to	  meet	  the	  demand	  of	  patients	  who	  are	  willing	  to	  cover	  
the	  cost	  of	  an	  expensive	  cancer	  drug	  that	  their	  province	  may	  have	  been	  unable	  to	  
fund,	  and	  allowing	  the	  patient	  access	  to	  the	  treatment	  (Flood,	  Hardcastle	  2007).	  	  
These	  clinics	  are	  expensive	  as	  they	  have	  significant	  overhead	  costs	  and	  require	  a	  
specially	  trained	  staff.	  Additionally,	  they	  are	  not	  as	  abundant	  as	  patients	  would	  like	  
and	  this	  has	  led	  to	  patients	  requesting	  the	  ability	  to	  purchase	  these	  drugs	  and	  have	  
them	  administered	  in	  their	  local	  hospital	  or	  private	  clinic	  (CanWest	  MediaWorks	  
Publications	  Inc	  2007).	  If	  cancer	  drugs	  were	  more	  funded	  adequately	  and	  equitably	  
funded	  across	  the	  country,	  there	  wouldn’t	  be	  a	  need	  for	  private	  clinics.	  	  
2.2	  Australia	  
	  
Australia’s	  healthcare	  is	  a	  complicated	  mix	  of	  commonwealth	  and	  
government	  state	  funded	  initiatives	  as	  well	  as	  private	  insurance	  (Australian	  
Institute	  of	  Health	  and	  Welfare	  2012).	  While	  is	  sounds	  complex,	  the	  Australian	  
healthcare	  system	  reportedly	  delivers	  above-­‐average	  health	  outcomes	  (Faden,	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Chalkidou	  et	  al.	  2009).	  	  In	  2009,	  it	  was	  reported	  that	  the	  Australian	  government	  
spent	  $5	  billion	  dollars	  on	  cancer	  care	  (Australian	  Institute	  of	  Health	  and	  Welfare	  
2012,	  Karikios,	  Schofield	  et	  al.	  2014).	  	  A	  significant	  portion	  of	  that	  is	  spent	  on	  cancer	  
drugs.	  A	  study	  by	  Kariokis	  et	  al	  found	  that	  the	  expenditure	  on	  cancer	  drugs	  in	  
Australia	  rose	  from	  $64.8	  million	  in	  1999-­‐2000	  to	  over	  $560	  million	  in	  2011-­‐2012	  
(Australian	  Institute	  of	  Health	  and	  Welfare	  2012,	  Karikios,	  Schofield	  et	  al.	  2014).	  
The	  study	  also	  found	  that	  the	  median	  cost	  to	  the	  Pharmaceutical	  Benefits	  Scheme	  
(PBS)	  for	  a	  year	  of	  a	  new	  cancer	  drug	  treatment	  was	  $60,000	  (Australian	  Institute	  of	  
Health	  and	  Welfare	  2012,	  Karikios,	  Schofield	  et	  al.	  2014).	  	  
The	  body	  responsible	  for	  making	  drug	  recommendations	  on	  the	  public	  
reimbursement	  of	  new	  drugs	  is	  the	  Pharmaceutical	  Benefit	  Advisory	  Committee	  
(PBAC).	  Similar	  to	  many	  regulatory	  bodies,	  the	  PBAC	  partly	  makes	  
recommendations	  based	  on	  the	  cost-­‐effectiveness	  of	  a	  drug	  following	  approval	  by	  
the	  Therapeutic	  Goods	  Administration	  (Chustecka	  2013).	  However,	  as	  a	  result	  of	  
their	  two-­‐tiered	  system	  with	  public	  and	  private	  insurance,	  there	  is	  a	  lot	  of	  variability	  
in	  patient	  care	  and	  access	  to	  cancer	  drugs.	  Now,	  any	  drug	  estimated	  to	  cost	  more	  
than	  $20	  million	  dollars	  per	  year	  must	  undergo	  further	  approval	  by	  the	  Minister	  of	  
Health	  who	  then	  signs	  off	  on	  the	  final	  decision.	  	  If	  a	  drug	  is	  not	  on	  the	  
reimbursement	  list,	  it	  is	  unavailable	  to	  patients	  unless	  they	  can	  afford	  to	  cover	  the	  
full	  costs,	  as	  private	  insurance	  does	  not	  cover	  the	  costs	  of	  chemotherapy	  (Chustecka	  
2013).	  Like	  every	  country,	  fiscal	  considerations	  come	  first	  and	  fore	  front.	  However,	  
occasionally	  negotiations	  between	  the	  drug	  manufacturer	  and	  Government	  are	  
unsuccessful	  and	  represent	  a	  significant	  hindrance	  in	  the	  access	  to	  new	  cancer	  
	   13	  
medicines.	  The	  process	  for	  approval	  has	  been	  criticized	  for	  its	  lack	  of	  transparency.	  
In	  particular,	  the	  PBAC	  does	  not	  have	  clear	  guidelines	  for	  approving	  drugs	  by	  not	  
specifying	  a	  threshold	  for	  cost-­‐effectiveness	  (Medicines	  Australia	  Oncology	  Industry	  
Taskforce	  2013).	  Notably,	  Australia	  has	  the	  highest	  age-­‐standardized	  incidence	  of	  
cancer	  in	  the	  world	  (Dutch	  National	  Cancer	  Control	  Programme	  2010).	  Just	  like	  
many	  countries,	  the	  population	  seeks	  faster	  access	  to	  life-­‐enhancing	  breakthrough	  
drugs.	  One	  particular	  drug,	  Yervoy	  (ipillimumab),	  has	  been	  shown	  to	  extend	  
patients	  with	  metastatic	  melanoma	  survival	  by	  up	  to	  10	  years.	  	  The	  drug	  was	  only	  
recently	  added	  to	  the	  list	  of	  subsidized	  medications	  in	  June	  2013,	  almost	  a	  full	  year	  
after	  being	  approved	  in	  Canada	  and	  Germany,	  leading	  to	  a	  lot	  of	  frustration	  and	  




	   As	  of	  2006,	  all	  residents	  of	  the	  Netherlands	  are	  mandated	  to	  purchase	  
statutory	  health	  insurance	  (SHI)	  from	  private	  insurers.	  	  The	  policies	  are	  regulated	  
under	  the	  Dutch	  law.	  	  Of	  the	  OECD	  countries,	  the	  Netherlands	  has	  the	  highest	  
percentage	  of	  its	  healthcare	  funded	  by	  private	  insurance,	  at	  77%	  (OECD	  2013).	  	  
According	  the	  Dutch	  government,	  the	  Netherlands	  spends	  less	  on	  healthcare	  
and	  has	  been	  shown	  to	  have	  better	  healthcare	  outcomes	  (Davis,	  Schoen	  et	  al.	  2010).	  
However,	  with	  respect	  to	  cancer,	  the	  National	  Institute	  for	  Public	  Health	  and	  the	  
Environment	  (RIVM)	  announced	  that	  in	  the	  past	  six	  years	  (2006-­‐2012),	  the	  money	  
spent	  on	  cancer	  care	  as	  a	  percentage	  of	  the	  healthcare	  spending	  has	  almost	  doubled,	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going	  from	  %	  4.6	  to	  %	  8.7	  (DutchNews.nl	  2013)	  and	  has	  been	  the	  leading	  cause	  of	  
death	  in	  Netherlands	  for	  the	  past	  4	  years	  (The	  European	  Commission:	  Eurostat	  
2013).	  	  	  
	   The	  Netherlands	  is	  one	  of	  many	  countries	  in	  the	  EU	  that	  has	  recently	  
undertaken	  a	  National	  Cancer	  Control	  Programme	  (NCCP)	  to	  address	  the	  cancer	  
burden.	  The	  Dutch	  NCCP	  is	  an	  initiative	  that	  is	  neutral	  in	  terms	  of	  budget	  and	  that	  
would	  realize	  reallocation	  on	  the	  basis	  of	  priorities.	  The	  programme	  covers	  all	  
aspects	  of	  cancer	  control,	  ensures	  coherent	  priorities	  and	  measurable	  objectives	  
(Dutch	  National	  Cancer	  Control	  Programme	  2010).	  The	  goal	  of	  the	  program	  was	  not	  
to	  raise	  more	  funds	  for	  cancer	  care,	  but	  rather,	  to	  more	  efficiently	  allocate	  them.	  	   	  
What	  is	  most	  interesting	  about	  the	  Dutch	  health	  care	  system	  is	  that	  it	  is	  
entirely	  based	  on	  private	  insurers	  (van	  de	  Ven,	  Schut	  2008).	  As	  a	  result,	  the	  
provision	  of	  cancer	  care	  is	  the	  responsibility	  of	  each	  hospital	  (Dutch	  National	  Cancer	  
Control	  Programme	  2010).	  This	  means	  that	  cancer	  care	  actually	  varies	  from	  hospital	  
to	  hospital,	  despite	  the	  introduction	  of	  minimum	  standards	  (DutchNews.nl	  2014).	  
However,	  in	  contrast	  to	  many	  other	  countries	  with	  private	  insurers,	  the	  private	  
providers	  are	  highly	  regulated	  and	  the	  insurance	  plans	  are	  standardized.	  People	  are	  
welcome	  to	  change	  companies	  as	  they	  please,	  allowing	  for	  some	  competition	  in	  the	  
market.	  To	  prevent	  loss	  of	  profitability	  from	  chronically	  ill	  patients,	  they	  have	  a	  risk	  
equalization	  system	  where	  insurance	  companies	  are	  compensated	  for	  providing	  
service	  to	  those	  patients	  who	  need	  it	  most	  (van	  de	  Ven,	  Schut	  2008).	  	  It	  is	  a	  
sophisticated	  ex-­‐ante	  risk	  adjustment	  system	  that	  compensates	  companies	  for	  
actuarially	  health	  expenditure	  differentials	  that	  result	  from	  various	  socio-­‐
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demographic	  factors	  (Halbersma,	  Mikkers	  et	  al.	  ).	  It	  also	  helps	  to	  equalize	  the	  
playing	  field	  for	  insurance	  companies	  by	  allowing	  them	  to	  engage	  in	  price	  
competition	  for	  premium	  coverage	  (Schut,	  Van	  de	  Ven	  2005,	  Halbersma,	  Mikkers	  et	  
al.	  ).	  	  
In	  a	  scenario	  where	  a	  patient	  becomes	  ill	  and	  requires	  expensive	  therapies,	  
they	  are	  able	  to	  purchase	  more	  insurance	  to	  help	  them	  cover	  the	  costs.	  In	  reality,	  to	  
be	  able	  to	  afford	  a	  risk	  equalization	  system,	  the	  health	  care	  system	  is	  funded	  
through	  two	  streams:	  the	  health	  insurance	  act	  and	  a	  scheme	  for	  long-­‐term	  care	  
services	  under	  a	  regime	  of	  price	  and	  supply	  regulation	  (Exceptional	  Medical	  
Expenses	  Act).	  	  
2.3.1	  Expensive	  Therapies	  and	  Drug	  Pricing	  
	  
	   In	  Netherlands	  there	  are	  legal	  and	  regulatory	  mechanisms	  in	  place	  to	  control	  
drug	  pricing	  (Dutch	  Ministry	  of	  Health	  2011),	  but	  this	  is	  largely	  aimed	  at	  
wholesalers	  and	  retailers.	  In	  2005,	  they	  introduced	  competition	  into	  the	  
Netherlands	  hospital	  market	  (Halbersma,	  Mikkers	  et	  al.	  ).	  	  The	  problem	  with	  this	  is	  
that	  it	  only	  negotiates	  the	  cost	  of	  health	  services	  and	  not	  the	  drugs	  themselves	  but	  
has	  shown	  to	  reduce	  the	  cost	  of	  healthcare.	  	  Additionally,	  Netherlands	  is	  only	  
country	  of	  13	  surveyed	  that	  was	  shown	  not	  to	  have	  engaged	  in	  special	  pricing	  
agreements	  (SPAS)	  with	  drug	  manufacturers	  (Cheema,	  Gavura	  et	  al.	  2012).	  	  
	  	   Approximately	  20%	  of	  the	  costs	  of	  expensive	  drugs	  are	  covered	  in	  hospital	  
budgets	  while	  the	  other	  80%	  is	  covered	  by	  the	  Dutch	  Health	  Authority	  (Uyl-­‐de	  
Groot,	  de	  Groot	  et	  al.	  2010).	  	  The	  Medicines	  Evaluation	  Board	  (MEB)	  is	  responsible	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for	  marketing	  authorization	  of	  medicines	  based	  on	  criteria	  such	  as	  efficacy,	  safety	  
and	  quality,	  in	  addition	  to	  pharmacovigilance,	  and	  providing	  scientific	  advice	  
(Schurer	  ).	  New	  treatments	  are	  approved	  either	  via	  the	  MEB	  or	  via	  the	  European	  
Medicines	  Evaluation	  Agency	  (EMEA).	  	  The	  Dutch	  Health	  Authority	  makes	  the	  final	  
decision	  of	  whether	  or	  not	  expensive	  drugs	  will	  be	  considered	  for	  extra	  hospital	  
income	  after	  receiving	  an	  analysis	  of	  the	  therapeutic	  value	  and	  the	  budgetary	  impact	  
of	  the	  new	  drug	  (Uyl-­‐de	  Groot,	  de	  Groot	  et	  al.	  2010).	  	  This	  requires	  the	  submission	  of	  
health	  economic	  data	  comparable	  with	  the	  UK,	  Canada	  and	  Australia.	  	  
Most	  medicines	  are	  reimbursed	  through	  health	  insurance	  and	  while	  
necessary	  medicines	  for	  particular	  conditions	  are	  publicly	  provided	  free	  of	  cost	  
(Table	  1).	  
	  
Table	  1.	  Adapted	  from	  (Stolk,	  Rutten	  ).	  
Condition	   Covered	  
Tuberculosis	   Yes	  
HIV/AIDS	   Yes	  
Sexually	  transmitted	  diseases	   Yes	  




If	  the	  medicines	  are	  not	  reimbursed	  or	  only	  partially	  reimbursed,	  then	  the	  patient	  is	  
responsible	  for	  the	  rest	  of	  the	  fees.	  Patients	  can	  potentially	  pay	  up	  to	  80%	  of	  the	  
cost	  of	  an	  expensive	  drug	  but	  may	  be	  able	  to	  purchase	  additional	  insurance	  to	  cover	  
the	  costs	  (Stolk,	  Rutten	  ).	  Under	  certain	  conditions,	  however,	  new	  expensive	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therapies	  for	  life-­‐threatening	  illnesses	  may	  be	  available	  under	  centrally	  subsidized	  
provisions	  (Stolk,	  Rutten	  ).	  The	  Dutch	  health	  care	  system	  classifies	  expensive	  
treatments	  or	  “dure	  geneesmiddellen”,	  as	  therapeutics	  that	  exceed	  a	  cost	  of	  
€500/prescription.	  Not	  surprisingly,	  oncology	  drugs	  comprise	  almost	  half	  of	  the	  
cost	  of	  these	  expensive	  treatments	  yet	  oncology	  patients	  pay	  no	  out-­‐of-­‐pocket	  costs	  
for	  these	  drugs	  (Schurer	  ).	  	  In	  the	  Netherlands	  cost	  effectiveness	  thresholds	  are	  
higher	  than	  for	  countries	  such	  as	  the	  UK	  (20–80,000£/QALY	  gained)	  and	  based	  on	  
disease	  severity	  and	  medical	  need,	  meaning	  high	  cost	  drugs	  are	  more	  often	  
approved	  there	  than	  other	  EU	  countries	  (Aggarwal,	  Ginsburg	  et	  al.	  ).	  
Similar	  to	  Australia,	  the	  Netherlands	  do	  not	  have	  a	  formalized	  threshold	  
value	  to	  indicate	  cost-­‐effectiveness	  (Boersma,	  Broere	  et	  al.	  2010).	  But	  unlike	  the	  
Australian	  system,	  the	  Dutch	  health	  care	  system	  has	  one	  of	  the	  highest	  satisfaction	  
rates	  in	  the	  world	  (van	  de	  Ven,	  Schut	  2008).	  They	  consume	  relatively	  less	  
pharmaceuticals	  than	  other	  countries,	  but	  manage	  to	  have	  one	  of	  the	  highest	  per	  
capita	  expenditures	  on	  healthcare	  and	  cancer	  care	  (OECD	  2013,	  Aggarwal,	  Ginsburg	  
et	  al.	  ).	  	  
	  
2.4	  The	  United	  Kingdom	  
	   	  
The	  U.K.’s	  National	  Health	  Service	  (NHS)	  was	  established	  in	  1948	  and	  is	  
funded	  by	  the	  government	  through	  a	  taxation	  system,	  similar	  to	  Canada.	  It	  is	  
universal	  and	  free	  for	  all	  residents	  of	  the	  U.K.	  with	  the	  exception	  of	  some	  co-­‐pay	  
services.	  Budgets	  are	  reviewed	  every	  three	  years	  by	  the	  government	  and	  approved	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by	  Parliament.	  There	  is	  also	  a	  very	  small	  segment	  of	  the	  market	  that	  is	  privatized	  
(Faden,	  Chalkidou	  et	  al.	  2009,	  Tapay,	  Colombo	  2004).	  	  Notably,	  a	  study	  by	  
Reinhardt,	  Hussey	  and	  Andersen	  found	  that	  the	  prices	  of	  expensive	  drugs	  in	  this	  
privatized	  segment	  were	  cheaper	  than	  the	  listing	  prices	  in	  the	  U.S.	  market	  
(Reinhardt,	  Hussey	  et	  al.	  2004).	  
	   One	  of	  the	  strengths	  of	  the	  U.K.’s	  system	  is	  that	  it’s	  got	  one	  of	  the	  least	  
restrictive	  pharmaceutical	  pricing	  and	  reimbursement	  in	  the	  world	  (Faden,	  
Chalkidou	  et	  al.	  2009).	  	  Following	  a	  drug’s	  regulatory	  approval,	  it	  is	  available	  for	  a	  
set	  price	  that	  is	  determined	  by	  the	  manufacturer.	  Eventually,	  almost	  all	  drugs	  
because	  available	  through	  the	  NHS.	  When	  an	  expensive	  therapy	  comes	  along	  that	  
has	  the	  potential	  to	  incur	  significant	  costs	  to	  the	  NHS,	  a	  central	  decision	  must	  take	  
place	  in	  order	  to	  decide	  whether	  make	  the	  drug	  available	  to	  all	  NHS	  patients.	  	  The	  
National	  Institute	  for	  Health	  and	  Clinical	  Excellence	  (NICE),	  established	  in	  1999	  to	  
determine	  which	  drugs	  offer	  significant	  clinical	  benefit	  and	  cost	  effectiveness,	  plays	  
a	  major	  role	  in	  the	  decision	  process	  (Pearson,	  Rawlins	  2005,	  Faden,	  Chalkidou	  et	  al.	  
2009).	  	  NICE	  considers	  a	  drug	  cost-­‐effective	  if	  it	  costs	  under	  £20,000	  per	  QALY,	  and	  
drugs	  over	  £30,000	  per	  quality-­‐adjusted	  life	  year	  (QALY)	  are	  generally	  considered	  
not	  to	  be	  a	  worthwhile	  investment	  for	  the	  NHS	  (McCabe,	  Claxton	  et	  al.	  2008).	  Drugs	  
that	  fall	  in	  between	  require	  some	  other	  justification	  for	  acceptance.	  Although	  in	  past	  
years,	  the	  system	  has	  come	  under	  criticism	  for	  having	  a	  low	  threshold	  range	  per	  
QALYs,	  while	  others	  disagree	  (Garau,	  Shah	  et	  al.	  2011).	  
	   A	  study	  by	  Richards	  indicated	  that	  since	  the	  establishment	  of	  NICE	  in	  1999,	  
approximately	  30%	  of	  their	  decisions	  have	  pertained	  to	  new	  cancer	  drugs	  (Richards	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2006).	  If	  the	  NICE	  fails	  to	  approve	  a	  drug,	  a	  patient	  in	  need	  can	  appeal	  the	  decision.	  
While	  the	  NHS	  may	  not	  fund	  the	  drug,	  individual	  PCTs	  can	  still	  choose	  to	  fund	  the	  
drug	  for	  the	  patient.	  Of	  the	  patient	  appeals	  made,	  approximately	  65%-­‐90%	  were	  
approved.	  	  This	  clearly	  illustrates	  the	  variability	  in	  drug	  access	  in	  the	  U.K.,	  similar	  to	  
the	  Canadian	  system	  prior	  to	  the	  PCPA.	  	  
2.5	  The	  United	  States	  	  
	   In	  a	  country	  without	  universal	  healthcare,	  how	  do	  people	  afford	  the	  price	  tag	  
on	  these	  new	  therapies?	  In	  2011,	  the	  US	  spent	  an	  estimated	  $2.7	  trillion	  on	  
healthcare,	  an	  estimated	  18%	  of	  their	  GDP	  (Kantarjian,	  Fojo	  et	  al.	  2013).	  According	  
to	  a	  2012	  IMS	  report	  on	  the	  global	  use	  of	  medicines,	  and	  a	  separate	  OECD	  study,	  the	  
US	  has	  the	  highest	  per	  capita	  expenditure	  on	  healthcare	  in	  the	  world	  (Appendix	  4)	  
(IMS	  Institute	  for	  Health	  Informatics	  2011).	  Total	  Medicare	  expenditures	  were	  
estimated	  at	  over	  $500	  million	  in	  2011	  (Himmelstein,	  Woolhandler	  2012).	  A	  study	  
by	  Cheema	  et	  al	  indicated	  that	  the	  US	  has	  some	  of	  the	  broadest	  access	  to	  publicly	  
funded	  cancer	  drugs	  (Cheema,	  Gavura	  et	  al.	  2012).	  
In	  contrast	  to	  many	  countries	  with	  universal	  healthcare,	  the	  U.S.	  has	  many	  
payers	  who	  use	  different	  standards	  and	  different	  processes	  to	  determine	  if	  a	  new	  
expensive	  cancer	  drugs	  should	  be	  purchased	  and	  reimbursed	  (Faden,	  Chalkidou	  et	  
al.	  2009).	  As	  a	  result,	  it	  is	  difficult	  to	  assess	  the	  access	  to	  cancer	  care	  and	  financing	  of	  
new	  and	  expensive	  therapies.	  	  Similar	  to	  Canada’s	  individual	  provincial	  formularies,	  
there	  are	  an	  excessive	  amount	  if	  formularies	  in	  the	  US,	  each	  affected	  by	  purchasing	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power,	  state	  laws,	  funding	  programs,	  and	  other	  factors	  (Faden,	  Chalkidou	  et	  al.	  
2009).	  As	  such,	  the	  federal	  government	  and	  some	  states	  address	  needs/deficiencies	  
directly.	  For	  example,	  the	  Breast	  and	  Cervical	  Cancer	  Prevention	  and	  Treatment	  Act	  
was	  created	  in	  2000.	  It	  is	  a	  Medicaid	  waiver	  that	  allows	  uninsured	  women	  who	  
would	  otherwise	  not	  be	  eligible	  for	  breast	  or	  cervical	  cancer	  treatment	  through	  
Medicaid.	  
	   A	  component	  of	  the	  Medicare,	  Part	  B,	  covers	  drugs	  that	  are	  administered	  in	  a	  
clinical	  setting.	  	  It	  is	  required	  to	  cover	  and	  cancer	  drug	  that	  has	  received	  a	  ‘medically	  
accepted	  indication’,	  which	  would	  include	  drugs	  and	  uses,	  approved	  by	  the	  FDA	  and	  
other	  sources	  (Bach	  2009,	  Faden,	  Chalkidou	  et	  al.	  2009).	  While	  approximately	  99%	  
of	  the	  population	  have	  Part	  B	  coverage	  and	  are	  therefore	  insured	  for	  these	  pricey	  
cancer	  therapies,	  they	  do	  not	  have	  full	  financial	  coverage.	  This	  can	  result	  in	  some	  
extremely	  high	  out-­‐of-­‐pocket	  costs	  for	  both	  drugs	  administered	  in	  a	  clinical	  setting	  
and	  prescriptions.	  
Interestingly,	  one	  of	  the	  major	  contributing	  factors	  to	  the	  high	  drug	  prices	  in	  
the	  US	  is	  the	  law.	  It	  is	  illegal	  for	  any	  government	  body	  (such	  as	  Medicare)	  to	  
negotiate	  lower	  drug	  prices,	  although	  other	  bodies,	  such	  as	  Veteran	  Affairs,	  are	  
allowed	  and	  do	  negotiate	  lower	  prices	  (25-­‐50%	  cheaper	  on	  average	  than	  Medicare)	  
(Kantarjian,	  Fojo	  et	  al.	  2013).	  In	  2003	  a	  Medicare	  drug	  benefit	  was	  extended	  and	  
additional	  provisions	  were	  added	  to	  the	  law,	  prohibiting	  government	  from	  
bargaining	  for	  prices	  on	  drugs	  (Kantarjian,	  Fojo	  et	  al.	  2013).	  Economist	  Dean	  Baker	  
estimated	  6	  years	  ago	  that	  without	  this	  provision,	  the	  government	  could	  have	  saved	  
	   21	  
an	  estimated	  50-­‐80	  billion	  per	  year	  on	  drug	  prices	  (Kantarjian,	  Fojo	  et	  al.	  2013,	  Lee,	  
Chertow	  et	  al.	  2009).	  In	  Obama’s	  proposed	  budget	  for	  2014,	  he	  requested	  for	  
Congress	  to	  require	  large	  drug	  companies	  to	  sell	  their	  medications	  to	  Medicare	  at	  
the	  best	  price	  they	  offer	  private	  insurance	  companies	  (Potter	  2013).	  
2.5.1	  The	  Affordable	  Care	  Act	  
	  
How	  does	  Obama’s	  Affordable	  Care	  Act	  affect	  this?	  	  Obamacare	  certainly	  has	  
its	  critics,	  particularly	  when	  it	  comes	  to	  its	  effects	  on	  people	  with	  life-­‐threatening	  
illnesses,	  but	  there	  is	  literature	  supporting	  its	  negative	  and	  positive	  attributes,	  with	  
respect	  to	  cancer	  patients.	  	  	  	  
The	  arguments	  against	  Obamacare	  with	  respect	  to	  cancer	  patients	  are	  
plentiful.	  First,	  people	  are	  concerned	  that	  the	  Affordable	  Care	  Act	  makes	  some	  of	  the	  
nation’s	  elite	  cancer	  clinics	  off-­‐limits	  for	  those	  insured	  (Associated	  Press	  2014).	  This	  
also	  means	  that	  existing	  cancer	  patients	  may	  no	  longer	  have	  access	  to	  the	  same	  
network	  of	  doctors	  they	  were	  seeing	  previously.	  	  	  
On	  the	  other	  hand,	  the	  American	  Cancer	  Society	  argues	  that	  the	  Affordable	  
Care	  Act	  will	  actually	  benefit	  those	  touched	  by	  cancer	  by	  largely	  increasing	  access	  to	  
cancer	  treatment.	  First,	  the	  act	  covers	  those	  who	  did	  not	  previously	  have	  insurance	  
to	  receive	  coverage	  as	  a	  part	  of	  each	  state’s	  high-­‐risk	  pools;	  as	  well,	  health	  plans	  are	  
now	  banned	  from	  setting	  annual	  dollar	  limits	  on	  treatment,	  ensuring	  patients	  will	  
no	  longer	  have	  to	  put	  off	  treatments	  until	  the	  new	  year	  (The	  American	  Cancer	  
Society	  2013).	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3.1	  Discussion	  
	   After	  reviewing	  the	  strategies	  of	  several	  countries,	  the	  majority	  with	  
universal	  healthcare,	  it	  begs	  the	  question-­‐	  how	  can	  you	  reduce	  healthcare	  spending	  
and	  still	  maintain	  the	  same	  efficacy	  and	  patient	  safety	  (or	  standard	  of	  care)?	  	  A	  
summary	  of	  health	  care	  expenditure	  can	  be	  seen	  in	  Appendices	  5	  &	  6.	  	  No	  one	  
country	  has	  a	  completely	  equitable	  health	  care	  system,	  but	  the	  Netherlands	  
undoubtedly	  comes	  the	  closest	  with	  their	  standardized,	  mandatory,	  insurance	  
policies.	  The	  question	  remains	  as	  to	  whether	  there	  is	  an	  optimal	  mix	  of	  public	  and	  
private	  health	  insurance.	  	  
While	  the	  sky-­‐high	  cost	  of	  new	  drugs	  may	  have	  logical	  roots,	  there	  is	  no	  
reason	  why	  drugs	  like	  Gleevec	  still	  cost	  $100,000	  a	  year	  (Cowley	  2013).	  Often	  times,	  
these	  costs	  are	  a	  result	  of	  large	  pharma	  trying	  to	  mitigate	  the	  loss	  in	  revenues	  that	  
occur	  when	  the	  patents	  on	  their	  drugs	  expire	  and	  a	  generic	  version	  is	  introduced.	  
With	  respect	  to	  Gleevec,	  the	  earliest	  of	  these	  patents	  expires	  in	  January	  2015,	  as	  per	  
the	  FDA	  Orange	  Book.	  The	  costs	  of	  drugs	  like	  Gleevec	  remain	  astronomically	  high,	  
despite	  having	  earned	  substantial	  profits	  and	  paid	  off	  the	  cost	  of	  its	  development	  
years	  ago.	  	  For	  example,	  in	  the	  US	  alone,	  the	  2013	  sales	  of	  Gleevec	  were	  $4.69	  
billion,	  the	  same	  as	  2012	  and	  2011	  (as	  per	  Novartis’	  product	  sales	  reports).	  
Assuming	  a	  conservative	  cost	  of	  development	  of	  $2	  billion,	  Gleevec	  has	  more	  than	  
recouped	  its	  costs.	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   It	  is	  clear	  that	  there	  is	  no	  one	  solution	  to	  the	  drug-­‐pricing	  dilemma.	  	  The	  
literature	  extensively	  describes	  the	  ubiquitous	  nature	  of	  these	  struggles	  facing	  
governments	  in	  affording	  new	  expensive	  therapies	  for	  patients.	  	  The	  rising	  cost	  of	  
new	  innovative	  therapeutics	  contributes	  to	  the	  fact	  that	  healthcare	  expenditure	  in	  
virtually	  every	  developed	  country	  is	  on	  the	  rise	  (IMS	  Institute	  for	  Health	  Informatics	  
2011).	  Based	  on	  the	  market	  landscape	  and	  existing	  data	  on	  the	  previously	  described	  
countries,	  there	  are	  three	  proposed	  solutions.	  First,	  allowing	  the	  government	  to	  
have	  more	  control	  over	  negotiating	  drug	  price,	  second,	  tying	  regulatory	  approval	  in	  
each	  country	  to	  drug	  price,	  and	  lastly,	  tying	  the	  drug	  price	  to	  expected	  patient	  
outcomes.	  All	  three	  options	  will	  require	  government	  intervention	  to	  mandate	  these	  
changes;	  that	  being	  said,	  they	  are	  not	  necessarily	  mutually	  exclusive	  either.	  	  	  
3.1.1	  Government	  Negotiations	   	  
	  
In	  the	  US,	  a	  simple	  change	  such	  as	  giving	  Medicare	  the	  ability	  to	  negotiate	  the	  
cost	  of	  drugs	  would	  save	  the	  government	  billions	  of	  dollars	  each	  year.	  Canada	  has	  
already	  taken	  a	  step	  in	  the	  right	  direction	  by	  forming	  the	  PCPA,	  allowing	  them	  to	  
negotiate	  with	  drug	  manufacturers	  on	  behalf	  of	  all	  participating	  provinces.	  While	  
the	  PCPA	  sounds	  good	  in	  theory,	  the	  system	  has	  many	  critics	  in	  terms	  of	  its	  
execution	  (Dempster,	  Blanchard	  et	  al.	  2013).	  
	   If	  drug-­‐pricing	  schemas	  are	  ever	  going	  to	  change,	  it	  will	  require	  actions	  that	  
could,	  in	  effect,	  significantly	  impact	  the	  sales	  of	  expensive	  drugs.	  Take	  the	  case	  of	  
Zaltrap	  as	  an	  example.	  	  One	  major	  cancer	  center	  in	  the	  US	  decided	  against	  funding	  
Zaltrap,	  largely	  due	  to	  cost.	  This	  in	  turn	  resulted	  in	  the	  drug	  manufacturer	  slashing	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the	  cost	  by	  approximately	  half.	  	  The	  economic	  reality	  is	  that	  the	  U.S.	  is	  the	  largest	  
pharmaceutical	  market	  in	  the	  world	  by	  value	  (IMS	  Institute	  for	  Health	  Informatics	  
2011).	  	  The	  primary	  customers	  in	  the	  US	  are	  not	  patients	  or	  doctors.	  The	  customers	  
are	  the	  government	  (through	  Medicare	  and	  Medicaid)	  and	  private	  insurance	  
companies.	  And	  since	  the	  insurer	  or	  government	  is	  picking	  up	  the	  check,	  companies	  
can	  and	  do	  set	  prices	  that	  few	  individuals	  could	  pay.	  In	  the	  jargon	  of	  economics,	  the	  
demand	  for	  therapeutic	  drugs	  is	  “price	  inelastic”:	  increasing	  the	  price	  doesn’t	  
reduce	  how	  much	  the	  drugs	  are	  used.	  Prices	  are	  set	  and	  raised	  according	  to	  what	  
the	  market	  will	  bear,	  and	  the	  parties	  who	  actually	  pay	  the	  drug	  companies	  will	  meet	  
whatever	  price	  is	  charged	  for	  an	  effective	  drug	  to	  which	  there	  is	  no	  alternative.	  
Governments	  could	  be	  encouraged	  to	  set	  maximum	  allowable	  prices,	  similar	  to	  how	  
some	  governments	  regulate	  the	  cost	  of	  generic	  drugs.	  This	  approach	  would	  
effectively	  help	  bring	  down	  the	  cost	  of	  expensive	  new	  therapies,	  while	  allowing	  drug	  
companies	  to	  recoup	  their	  costs	  over	  time.	  	  
3.1.2	  Regulatory	  Approval	  and	  Expected	  Life	  Outcomes	  
	   Prior	  to	  a	  new	  drug	  being	  sold	  in	  a	  new	  market,	  it	  must	  receive	  approval	  
from	  the	  governing	  regulatory	  body,	  such	  as	  the	  EMEA,	  FDA	  or	  Health	  Canada.	  After	  
this,	  the	  drug	  can	  be	  legally	  purchased	  in	  that	  market.	  The	  decision	  by	  the	  
regulatory	  body	  does	  take	  into	  account	  cost-­‐effectiveness.	  	  That	  part	  of	  the	  process	  
occurs	  afterwards	  when	  either	  pCODR	  or	  the	  CDR	  reviews	  it.	  There	  is	  little	  or	  no	  
correlation	  between	  a	  drug’s	  efficacy	  and	  its	  price,	  but	  maybe	  there	  should	  be	  
(Hillner,	  Smith	  2009).	  In	  a	  free	  market,	  one	  would	  expect	  the	  price	  to	  eventually	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settle	  and	  reflect	  the	  true	  benefit,	  but	  that	  doesn’t	  happen.	  Of	  the	  12	  drugs	  approved	  
by	  the	  FDA	  for	  cancer	  treatment	  in	  2012,	  only	  3	  prolonged	  survival	  (2	  of	  the	  drugs	  
by	  only	  2	  months),	  and	  ¾	  of	  them	  cost	  over	  $10,000	  per	  month	  (Kantarjian,	  Fojo	  et	  
al.	  2013).	  
	   Drug	  approval	  should	  be	  directly	  tied	  to	  more	  parameters	  than	  just	  safety	  
and	  efficacy.	  It	  should	  also	  assess	  cost,	  and	  the	  cost	  associated	  with	  QALYs.	  	  For	  
example,	  a	  drug	  that	  confers	  6	  months	  of	  progression/disease	  free	  survival	  (PFS)	  
should	  cost	  more	  than	  a	  drug	  that	  increased	  life	  expectancy	  by	  1	  month.	  	  In	  this	  way,	  
drugs	  could	  be	  categorized	  based	  on	  various	  levels	  of	  efficacy	  and	  costs	  assigned	  
accordingly.	  It	  would	  also	  act	  as	  an	  incentive	  for	  pharmaceutical	  companies	  to	  
develop	  therapies	  that	  prolong	  PFS	  and	  a	  better	  quality	  of	  life	  as	  opposed	  to	  pushing	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4.1	  Conclusion	  
	   	  
There	  is	  a	  lot	  of	  literature	  citing	  the	  astronomical	  cost	  of	  drug	  development	  
(Baras,	  Baras	  et	  al.	  2012,	  Morgan,	  Grootendorst	  et	  al.	  2011,	  DiMasi,	  Grabowski	  
2007),	  which	  may	  be	  inflated	  for	  the	  sake	  of	  Big	  Pharma	  (Kantarjian,	  Fojo	  et	  al.	  
2013).	  However,	  the	  pharmaceutical	  industry	  remains	  highly	  profitable,	  at	  least	  in	  
North	  America,	  despite	  concerns	  that	  it	  is	  an	  industry	  headed	  for	  crisis	  (Sams-­‐Dodd	  
2013).	  	  
The	  situation	  facing	  governments	  and	  access	  to	  cancer	  care	  is	  multi-­‐faceted.	  
They	  must	  ensure	  equal	  access	  without	  prejudice	  across	  jurisdictions	  in	  a	  way	  that	  
does	  not	  come	  with	  a	  negative	  social	  impact	  due	  to	  cost	  constraints.	  Multi-­‐tiered	  
health	  care	  insurance	  also	  complicates	  things,	  as	  those	  with	  a	  better	  socioeconomic	  
status	  are	  more	  often	  able	  to	  afford	  better	  care.	  	  Additionally,	  political	  forces	  
sometimes	  prohibit	  governments	  from	  fully	  leveraging	  their	  ability	  to	  negotiate	  
with	  drug	  manufacturers.	  	  	  
This	  paper	  suggests	  two	  key	  strategies	  for	  addressing	  the	  high	  cost	  of	  cancer	  
therapies.	  	  The	  first,	  giving	  governments	  the	  ability	  to	  negotiate	  drug	  costs	  on	  a	  
large	  scale,	  as	  well	  as	  tying	  drug	  approval	  to	  acceptable	  costs	  by	  setting	  maximum	  
allowable	  pricing	  schemes.	  	  Secondly,	  re-­‐structuring	  drug	  costs	  based	  on	  
hierarchical	  pre-­‐determined	  ladder	  of	  health	  benefits	  to	  the	  patients.	  	  The	  
implementation	  of	  a	  particular	  solution	  addressing	  the	  cost	  issue	  is	  the	  hardest	  area	  
to	  address.	  	  Regardless,	  it	  seems	  that	  patients	  and	  governments	  are	  willing	  to	  pay	  
more	  for	  greater	  societal	  and	  personal	  benefits.	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  Advisory	  Committee	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